Allovir Inc (ALVR)

$2.15

-0.07

(-3.15%)▲

Market is closed - opens 7 PM, 02 Oct 2023

Insights on Allovir Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 82.6% return, outperforming this stock by 155.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 162.6% return, outperforming this stock by 254.9%

Performance

  • $2.14
    $2.26
    $2.15
    downward going graph

    0.47%

    Downside

    Day's Volatility :5.31%

    Upside

    4.87%

    downward going graph
  • $1.90
    $10.29
    $2.15
    downward going graph

    11.63%

    Downside

    52 Weeks Volatility :81.54%

    Upside

    79.11%

    downward going graph

Returns

PeriodAllovir IncSector (Health Care)Index (Russel 2000)
3 Months
-33.64%
-3.0%
0.0%
6 Months
-44.87%
-0.6%
-1.9%
1 Year
-72.15%
6.3%
6.3%
3 Years
-92.31%
22.5%
15.5%

Highlights

Market Capitalization
366.7M
Book Value
$2.08
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.79
Wall Street Target Price
19.75
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-45.04%
Return On Equity TTM
-86.07%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
165.0K
EBITDA
-173.6M
Diluted Eps TTM
-1.79
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.73
EPS Estimate Next Year
-1.63
EPS Estimate Current Quarter
-0.44
EPS Estimate Next Quarter
-0.42

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Allovir Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 818.6%

Current $2.15
Target $19.75

Technicals Summary

Sell

Neutral

Buy

Allovir Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Allovir Inc
Allovir Inc
-33.23%
-44.87%
-72.15%
-92.31%
-91.53%
Moderna, Inc.
Moderna, Inc.
-8.24%
-35.23%
-14.63%
47.49%
455.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.04%
-0.39%
11.95%
44.85%
108.75%
Novo Nordisk A/s
Novo Nordisk A/s
-3.92%
13.96%
77.36%
162.64%
290.64%
Seagen, Inc.
Seagen, Inc.
2.04%
5.02%
54.07%
7.21%
161.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.96%
9.93%
16.91%
27.14%
81.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Allovir Inc
Allovir Inc
NA
NA
NA
-1.73
-0.86
-0.45
0.0
2.08
Moderna, Inc.
Moderna, Inc.
34.94
34.94
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.08
22.08
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.05
43.05
2.03
1.64
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.67
26.67
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Allovir Inc
Allovir Inc
Buy
$366.7M
-91.53%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.2B
455.32%
34.94
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.6B
108.75%
22.08
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$412.6B
290.64%
43.05
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$39.8B
161.4%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$89.7B
81.52%
26.67
35.4%

Institutional Holdings

  • FMR Inc

    8.36%

  • Wasatch Advisors Inc.

    5.83%

  • Artal Group S A

    5.79%

  • Alkeon Capital Management, LLC

    4.04%

  • GMT Capital Corp

    3.60%

  • BlackRock Inc

    2.92%

Corporate Announcements

  • Allovir Inc Earnings

    Allovir Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

allovir, inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific t cell (vst) therapies to prevent and treat devastating viral-associated diseases. the company's lead product is viralym-m, an allogeneic, off-the-shelf vst therapy, to treat bk virus, cytomegalovirus, adenovirus, epstein-barr virus, and human herpesvirus 6. its preclinical and clinical development product candidates include alvr106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; alvr109 to treat sars-cov-2 and covid-19; alvr107 for treating hepatitis b; and alvr108 to treat human herpesvirus-8, including kaposi's sarcoma, primary effusion lymphoma, and multicentric castleman's diseases. the company was formerly known as viracyte, inc. and changed its name to allovir, inc. in may 2019. allovir, inc. was founded in 2013 and is based in cambridge, massachusetts.

Organization
Allovir Inc
Employees
113
CEO
Mr. David L. Hallal
Industry
Health Technology

Discover More

FAQs